Intravital microscopy (IVM) enables live imaging of animals at single-cell level, offering essential insights into cancer progression. This technique allows for the observation of single-cell ...

Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients ...

Charles River Laboratories International, Inc. (CRL) updated financial guidance for 2024. Revenue and non-GAAP earnings per share guidance have been narrowed and slightly raised from the midpoint ...

James Foster; Chairman of the Board, President, Chief Executive Officer; Charles River Laboratories International Inc Flavia Pease; Chief Financial Officer, Corporate Executive Vice President ...

Charles River Laboratories International Inc (NYSE:CRL) exhibits resilience despite a challenging market environment. Strategic acquisitions and a diversified service portfolio position CRL for ...

In a report released yesterday, Charles Rhyee from TD Cowen maintained a Hold rating on Charles River Labs (CRL – Research Report), with ...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a ...